EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)

Trial Profile

EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Everolimus (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE-II
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 12 Mar 2018 EVOLVE II 4-year data will be available for presentation for the first time at ACC 2018
    • 12 Mar 2018 Long term results (more than 3 years) presented at the 67th Annual Scientific Session of the American College of Cardiology
    • 24 Mar 2016 According to Boston Scientific media release, results will be published at the American College of Cardiology's 65th Annual Scientific Session.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top